Trials redesigned for precision care

Obesity drug trials are being rebuilt around a simple premise: patients often need years of treatment, so studies are stretching beyond short-term weight loss. (news-medical.net) A white paper published April 17, 2026, by contract research organization hVIVO says older obesity studies relied on short timelines and “blunt endpoints” that treated pounds lost as the main result. The paper says newer programs are asking how long benefits last, what happens after stopping treatment, and which outcomes matter to regulators and payers. (news-medical.net) The Food and Drug Administration’s January 2025 draft guidance points in the same direction. It covers both weight reduction and “long-term maintenance of body weight” and replaces the agency’s February 2007 draft on weight management products. (fda.gov) Europe has already framed obesity studies around broader benefit-risk questions. The European Medicines Agency says its weight-control guideline sets requirements for efficacy, safety, patient selection, and trial design, and notes earlier European approvals were suspended over cardiovascular and neuropsychiatric side effects. (ema.europa.eu) The science changed first. In the SURMOUNT-4 trial, adults who stayed on tirzepatide after a 36-week lead-in lost another 5.5% of body weight over 52 weeks, while those switched to placebo regained 14.0%. (jamanetwork.com) Semaglutide studies showed the same problem from the other side. In the STEP 1 extension, participants regained about two-thirds of their prior weight loss within one year after treatment stopped, pulling cardiometabolic improvements back toward baseline. (pmc.ncbi.nlm.nih.gov) That is why trial designers are moving from “Did the drug lower weight at one fixed date?” to “Did it change disease over time?” The American Association of Clinical Endocrinology’s 2025 obesity algorithm describes obesity as a complex, chronic disease and tells clinicians to focus on complications and health outcomes, not body mass index alone. (endocrinepractice.org) Drugmakers are also chasing endpoints beyond the scale. In the SELECT trial, semaglutide cut the risk of cardiovascular death, heart attack, or stroke in adults with overweight or obesity and prior cardiovascular disease, without diabetes, over a mean follow-up of 39.8 months. (nejm.org) More of the pipeline is now being built to test those longer-run outcomes directly. Eli Lilly’s SURMOUNT-MMO study, listed on ClinicalTrials.gov and updated January 12, 2026, is testing whether tirzepatide reduces morbidity and mortality in adults with obesity. (clinicaltrials.gov) The practical consequence is that obesity trials now look more like diabetes or heart-disease programs: longer follow-up, maintenance phases, and endpoints tied to illness, side effects, and event reduction. The question is no longer only how much weight patients lose by week 52, but what that loss changes by year three. (news-medical.net)